Insider Selling: Biodesix (NASDAQ:BDSX) CEO Sells 3,559 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 3,559 shares of the firm’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total value of $35,874.72. Following the transaction, the chief executive officer owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. This represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Scott Hutton also recently made the following trade(s):

• On Friday, January 16th, Scott Hutton sold 970 shares of Biodesix stock. The shares were sold at an average price of $8.15, for a total value of $7,905.50.

Biodesix Trading Down 0.5%

BDSX traded down $0.05 during mid-day trading on Wednesday, hitting $10.35. 86,859 shares of the stock were exchanged, compared to its average volume of 3,040,306. The firm’s fifty day moving average is $8.30 and its two-hundred day moving average is $7.95. Biodesix, Inc. has a 1-year low of $3.44 and a 1-year high of $20.40. The company has a market cap of $82.39 million, a PE ratio of -1.86 and a beta of 0.67. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11.

Hedge Funds Weigh In On Biodesix

A number of institutional investors and hedge funds have recently modified their holdings of the company. Aberdeen Group plc purchased a new position in Biodesix in the fourth quarter valued at $1,784,000. XTX Topco Ltd lifted its holdings in Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares in the last quarter. Oracle Investment Management Inc. purchased a new position in shares of Biodesix in the 3rd quarter valued at about $113,000. Finally, Millennium Management LLC purchased a new position in shares of Biodesix in the 3rd quarter valued at about $113,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BDSX shares. Wall Street Zen upgraded shares of Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.